Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil
A Global, Open-Label Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Inhaled LIQ861 (Treprostinil) in Pulmonary Arterial Hypertension (WHO Group 1) Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85006
- Banner University Medical Center
-
Phoenix, Arizona, United States, 85012
- Arizona Pulmonary Specialists, Ltd.
-
-
California
-
Los Angeles, California, United States, 90073
- West Los Angeles VA Healthcare Center
-
Sacramento, California, United States, 95817
- UC Davis Medical Center
-
Torrance, California, United States, 90502
- Los Angeles Biomedical Research Center
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado Anschutz Medical Campus
-
-
Florida
-
Gainesville, Florida, United States, 32610
- University of Florida
-
Jacksonville, Florida, United States, 32224
- Mayo Clinic-Jacksonville
-
Orlando, Florida, United States, 32803
- AdventHealth
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University School of Medicine
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- University of Chicago Medicine
-
Chicago, Illinois, United States, 60611
- Northwestern Medicine, Feinberg School of Medicine
-
-
Kansas
-
Kansas City, Kansas, United States, 66103
- University of Kansas Medical Center
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70121
- Ochsner Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02111
- Tufts Medical Center
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic-Rochester
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87106
- University of New Mexico Health Science Center
-
-
Ohio
-
Cincinnati, Ohio, United States, 45267
- University of Cincinnati Medical Center
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health and Science Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- UPMC Presbyterian Hospital
-
Pittsburgh, Pennsylvania, United States, 15212
- Alleghany General Hospital
-
-
Texas
-
Dallas, Texas, United States, 75390
- UT Southwestern Medical Center
-
Houston, Texas, United States, 77030
- Houston Methodist Lung Center
-
San Antonio, Texas, United States, 78229
- University of Texas Health Science Center at San Antonio
-
-
Virginia
-
Falls Church, Virginia, United States, 22042
- Inova Fairfax Medical Campus
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Evidence of a personally signed and dated informed consent document exists indicating that the patient has been informed of all pertinent aspects of the study prior to initiation of any study-related procedures.
- Patient is willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
- Patient has fulfilled all entry criteria at the time of enrollment in original study with LIQ861.
- Patient has completed the protocol defined end of study procedures or met a protocol-defined and adjudicated endpoint in the original LIQ861 study in which they were enrolled.
- Patient, whether male or female, agrees to use a medically acceptable method of contraception throughout the entire study period from informed consent through the termination visit, if the possibility of conception exists. Eligible male and female patients must also agree not to participate in a conception process (e.g., actively attempt to become pregnant or to impregnate, sperm donation, in vitro fertilization) during the study and for 30 days after the last dose of LIQ861.
Exclusion Criteria:
- Patient prematurely discontinued LIQ861 due to a drug-related AE/SAE or tolerability issue in the original LIQ861 study in which they were enrolled, or patient did not complete protocol defined study procedures at an end of study visit (not Early Termination visit) in their original LIQ861 study.
- Patient withdrew consent during participation in another LIQ861 study.
- Patient is a female who wishes to become pregnant or who has a positive pregnancy test on Day 1 (LTI-302 Study Initiation Visit).
- Patient has undergone lung or heart/lung transplant or the initiation of parenteral (intravenous [IV] infusion or subcutaneous injection) therapy with a prostacyclin during the time since participation in their original LIQ861 study.
- Any reason exists that, in the opinion of the Investigator or Medical Monitor, precludes the patient from participating in the study, e.g., any previous or intercurrent medical condition that may increase the risk associated with study participation or that would confound study analysis or impair study participation or cooperation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: LIQ861 Inhaled Treprostinil
LIQ861 inhaled treprostinil at capsule strengths of 25 μg, 50 μg, 75 μg and 100 μg.
LIQ861 will be administered using the RS00 Model 8 dry powder inhalation (DPI) device (Plastiape S.p.A.; Osnago, Italy) at dose levels of 25 μg capsule strength to 200 μg capsule strength treprostinil four times a day (QID) in individual patients.
Titrating to dose levels beyond 200 μg capsule strength QID, under clinical investigator supervision, requires review and approval from the Medical Monitor.
|
LIQ861 bulk powder is generated from a treprostinil/excipient matrix from which particles of precise size and shape are created and filled into a hydroxypropyl methylcellulose (HPMC) capsule (size 3).
LIQ861 capsules are provided in capsule strengths of 25 μg, 50 μg, 75 μg and 100 μg treprostinil.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants with treatment emergent adverse events (AEs).
Time Frame: Baseline until the end of study, approximately 2.5 years (Dec-2021).
|
Treatment-emergent adverse events and serious adverse events will be grouped by MedDRA System Organ Class, dose level at onset, time on drug at onset, and relationship to dose titration.
|
Baseline until the end of study, approximately 2.5 years (Dec-2021).
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Nicholas S Hill, MD, Tufts Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- LTI-302
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.